WHO cheers COVID-19 trial results of dexamethasone
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus on Tuesday called initial clinical trial results of a steroid shown to reduce deaths in critically ill coronavirus patients “great news.”
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus on Tuesday called initial clinical trial results of a steroid shown to reduce deaths in critically ill coronavirus patients “great news.”
“This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” Ghebreyesus said of dexamethasone, which reduced the mortality of those on ventilators in the trial by one-third. “This is great news and I congratulate the Government of the UK, the University of Oxford, and the many hospitals and patients in the UK who have contributed to this lifesaving scientific breakthrough."
Currently, 50 percent of COVID-19 patients who need a ventilator don’t survive, according to BBC News. Dexamethasone, which has been used since the 1960s as an anti-inflammatory for arthritis and asthma patients, is inexpensive and widely available. Click here for more.
Other related developments:
- Dr. Marc Siegel hails results of research into dexamethasone as 'sign of hope' in coronavirus fight
- Researcher says coronavirus lockdowns cost US economy $1T without saving many lives
- Fauci recommends MLB season ending in September over COVID-19 fears
- Dr. Marc Siegel hails results of research into dexamethasone as 'sign of hope' in coronavirus fight
- Researcher says coronavirus lockdowns cost US economy $1T without saving many lives
- Fauci recommends MLB season ending in September over COVID-19 fears
.png)
No hay comentarios:
Publicar un comentario